We noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Toxicology of the cardiovascular system (1)
- Toxicology of the cardiovascular system (2)
- Drugs removed from market due to CV safety
- Toxicology of the cardiovascular system (3)
- Cardiovascular toxicity and adverse activity
- Adverse outcomes
- CV toxicology and safety pharmacology
- Cardiovascular safety assessment: strategy
- Types of nonclinical studies (1)
- Acute and repeat-dose toxicology studies
- Design of the GLP toxicology studies
- Structural changes in heart (histopathology)
- Cardiomyocyte's vacuolization after doxorubicin
- Cardiac hypertrophy with rosiglitazone
- Heart failure with rosiglitazone
- Cardiotoxicity with rosiglitazone
- Cardiotoxicity with rosiglitazone - benefit to risk
- Strengths and limitations of toxicology studies
- Problems and options of toxicology studies
- Safety pharmacology studies
- Safety pharmacology cardiovascular studies
- In vitro IKr assay
- In vitro ion channel assay
- Screens for Ikr inhibitory activity
- The GLP CV safety pharmacology studies
- Canine telemetry
- Canine external telemetry
- Strengths and limitations of cardiovascular studies
- Alternative cardiovascular assessment assays
- Cardiovascular toxicology
- Drug-induced Torsade de pointes
- Drugs removed due to Torsade de pointes
- In vivo QT interval duration
- Screens for proarrhythmic risk
- Case study: torcetrapib
- ILLUMINATE results
- Pharmacology investigation of torcetrapib (1)
- Pharmacology investigation of torcetrapib (2)
- Torcetrapib - summary and conclusions
- Sibutramine hydrochloride monohydrate
- SCOUT trial of sibutramine (1)
- SCOUT trial of sibutramine (2)
- Case study: sibutramine
- Safety pharmacology cardio studies - conclusions
- Types of nonclinical studies (2)
- In vitro assays and screens
- Safety testing in animal models of disease
- Biomarkers and predictive toxicology studies
- Biomarkers for cardiovascular toxicity (1)
- Biomarkers for cardiovascular toxicity (2)
- Biomarkers for cardiac toxicity
- Ongoing clinical trial - biomarkers
- Predictive cardiovascular toxicology
- Summary
- Thank you
Topics Covered
- Cardiovascular toxicities and adverse events in drug development programs
- CV drug removals from market
- Scientific perspective
- Regulatory perspective
- Strategies for minimising risks of CV toxicity in drug development programs
- Strategies for managing risks of CV toxicity in drug development programs
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Siegl, P. (2020, March 19). Toxicology of the cardiovascular system [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved May 29, 2023, from https://hstalks.com/bs/2056/.Export Citation (RIS)
Publication History
Financial Disclosures
- Dr. Peter Siegl has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
